Flexion Therapeutics, Inc.
- Jurisdiction
United States - LEI
549300X8HYW1HZKCDG90 - ISIN
US33938J1060 (FLXN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. Read full profile
Stock price
Fundamentals
- Net revenue
€86.14M - Gross margin
78.9% - EBIT
-€67.34M - EBIT margin
-78.2% - Net income
-€86.42M - Net margin
-100.3%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: August 4, 2021